Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.

The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.The market was less than impressed with the top-line results from Viking Therapeutics' (VKTX 1.73%) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created the sense that the stock lacks any near-term catalysts -- phase 3 results from VK2735 in subcutaneous (injection) form aren't likely until 2027 -- and that the excitement around the stock was primarily cente ...